Quectel Announces New Generation 5G Release 17 Module Series to Address Growing 5G FWA and eMBB Markets
MWC BARCELONA – Quectel Wireless Solutions, a global IoT solutions provider, today announces the launch of its latest generation 5G New Radio (NR) module series, the RG650E and RG650V, both of which follow the 3GPP Release 17 standard. These industrial grade 5G modules deliver enhanced performance in data rates, capacity, power saving, and latency as well as ultra-reliability, better addressing the growing 5G fixed wireless access (FWA), enhanced mobile broadband (eMBB), and industrial automation markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230226005190/en/
Quectel announces new generation 5G Release 17 module series to address growing 5G FWA and eMBB markets (Photo: Business Wire)
Based on the latest Snapdragon® X75 and X72 5G Modem-RF Systems from Qualcomm Technologies, Inc., the RG650E and RG650V series can work on both 5G non-standalone (NSA) and standalone (SA) modes. The RG650E supports a maximum bandwidth of 300 MHz in the sub-6GHz spectrum while the RG650V supports up to 200 MHz bandwidth. The adoption of Option 3x/ 3a/ 3 and Option 2 network architectures makes the modules backward compatible with global LTE and WCDMA networks.
Quectel also provides an RG650x-based System-on-Chip (SoC) solution with the latest Wi-Fi 7 technology, which significantly increases transfer speeds, reduces latency, and boosts overall network capacity for customer applications. Additionally, the module’s support of OpenWRT allows it to provide advanced networking features in a wider range of upstream ecosystem applications.
Integrated with a Quad-Core A55 processor, the RG650E and RG650V support 5G NR downlink carrier aggregation (CA), greatly improving data rates to meet the demand for super high data speeds in IoT verticals and applications, especially for FWA devices like CPE, home gateway, enterprise gateway, industrial router, mobile hotspot, eMBB terminals including high-definition live broadcast, AR/VR device, drone as well as industrial automation applications such as automated guided vehicles (AGV), remote control, and robot.
“We are excited to roll out the industry’s most advanced 5G NR modules based on the cutting-edge Snapdragon X75 and X72,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Our latest 5G NR Release 17 modules feature unprecedented performance and significant advantages in communication capability. I believe they will provide an excellent Sub-6GHz, mmWave and Wi-Fi 7 solution for the growing 5G FWA and eMBB markets.”
“Snapdragon X75 and X72, the world’s first 5G Advanced-ready modem-RF system provides unparalleled features and capabilities for performance, power efficiency, and flexibility making it the ideal solution for various highly demanding applications and use cases,” said Gautam Sheoran, vice president, product management, Qualcomm Technologies, Inc. “We are excited to see Quectel adopting our new modem-RF systems to drive the next stage of 5G evolution in all key verticals including FWA, home getaways, Industrial IoT, and more.”
The RG650E and RG650V series supports Qualcomm® Location Suite with Qualcomm® GNSS HW Gen 9.v6 (Concurrent GPS, BeiDou, Galileo, GLONASS, NavIC, and QZSS). The integrated GNSS receiver greatly simplifies product design and provides quicker, more accurate, and more dependable positioning capability for applications in any environment. Additionally, they provide a wide range of interfaces such as USXGMII, PCIe, USB 2.0/ 3.0/ 3.1, PCM and supplementary functions including VoLTE and VoNR.
The Quectel 5G module offering is complemented by its range of antennas which help optimize connection efficiency and aid ease of installation of devices. These can be supplied pre-integrated with Quectel IoT modules to accelerate time to market and help eliminate commonly found integration issues.
Engineering samples of the RG650E and RG650V will be available for global markets in the first half of 2023. To learn more, visit the Quectel booth at MWC Barcelona 2023, Hall 5, Booth 5A20.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
Snapdragon and Qualcomm are trademarks or register trademarks of Qualcomm Incorporated.
Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230226005190/en/
Contact information
Media:
Phil Rawcliffe, Head of Communications
phil.rawcliffe@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom